| Amgen is a biotechnology company that discovers, develops, manufactures and delivers human therapeutics. Co.'s products include: Enbrel® (etanercept), which is used in indications for the treatment of adult patients with moderately to severely active rheumatoid arthritis, patients with chronic moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy and patients with active psoriatic arthritis; and Prolia® (denosumab), which is used for the treatment of postmenopausal women with osteoporosis at high risk of fracture or multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. We show 45 historical shares outstanding datapoints in our coverage of AMGN's shares outstanding history.|
Understanding the changing numbers of AMGN shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like AMGN versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching AMGN by allowing them to research AMGN shares outstanding history
as well as any other stock in our coverage universe.